Respira Project: Humanistic and Economic Burden of Asthma in Brazil
Overview
Pulmonary Medicine
Authors
Affiliations
Objective: To determine the association of asthma on health-related quality of life (QoL), productivity, and use of healthcare resources among adults in Brazil.
Methods: Data were analyzed from the 2015 Brazil National Health and Wellness Survey, a cross-sectional survey with 12,000 adult respondents. Asthma and control groups were compared with respect to health-related QoL, asthma control, work productivity, and adherence. Generalized linear models were developed to compare asthma-related associations controlling for potential confounding factors.
Results: Among respondents, 4.1% (n = 494) reported an asthma diagnosis; those without asthma symptoms were used as the control group (n = 11,487). Regarding asthma control, 51.2% of patients had uncontrolled asthma, 36.4% partially controlled asthma, and 12.3% were fully controlled. Short-acting β2 agonists were the most commonly used class of drugs (38.5%). Approximately 32.4% of asthma patients were considered fully adherent to their treatment. In multivariable analyses, asthma patients presented lower health-related QoL and had more frequent visits with medical healthcare providers (6.1 versus 4.2) emergency room visits (1.0 versus 0.5), and more hospitalizations (0.4 versus 0.2), than control respondents six months prior to the study (p < 0.05). Rates of absenteeism and presenteeism varied between 11.5% and 7.4% (p < 0.05) and 30.4% and 20.9% (p < 0.001) between asthma patients and controls, respectively.
Conclusions: Asthma had a negative association on health-related QoL, work productivity, and use of healthcare resources. Excessive use of short-acting β2 agonists and poor treatment adherence reflect poor asthma control and suggest the need to implement new strategies for asthma treatment in Brazil.
Benson V, Siddall J, Haq A, Small M, Alfonso-Cristancho R, Tang Z J Asthma Allergy. 2024; 17:949-964.
PMID: 39371223 PMC: 11451406. DOI: 10.2147/JAA.S460300.
Overprescription of short-acting β2 agonists: reflections from the SABINA study in Brazil.
Antila M, Souza-Machado A, Gregorio M, Cruz A, Angelini L, Beekman M J Bras Pneumol. 2024; 50(1):e20230174.
PMID: 38422337 PMC: 11095926. DOI: 10.36416/1806-3756/e20230174.
In-silico identification and prioritization of therapeutic targets of asthma.
Mallick I, Panchal P, Kadam S, Mohite P, Scheele J, Seiz W Sci Rep. 2023; 13(1):15706.
PMID: 37735578 PMC: 10514284. DOI: 10.1038/s41598-023-42803-w.
The challenges of asthma care in low- and middle-income countries: what's next?.
Pitrez P J Bras Pneumol. 2023; 49(3):e20230215.
PMID: 37493795 PMC: 10578922. DOI: 10.36416/1806-3756/e20230215.
Cooper P, Figueiredo C, Rodriguez A, Dos Santos L, Ribeiro-Silva R, Carneiro V Clin Transl Allergy. 2023; 13(3):e12232.
PMID: 36973960 PMC: 10041090. DOI: 10.1002/clt2.12232.